Program
Flurbiprofen
Also written as “flurbiprofen”, “Flurbiprofen tablet” and “Flurbiprofen 100 mg”.
Its studies are mostly in Pharyngitis · HIV Infections · Diabetes Mellitus, Type 2 · Anemia · Periodontitis, led by 7 companies.
Drug pageFlurbiprofen: every studyMany companies study it; this page follows only the 12 they lead. All 31 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKlineits history only | 40 open or running | phase 1since Mar 1, 2007 | Mar 1, 2007 | none ahead |
| Reckittits history only | 30 open or running | phase 3since Jan 13, 2010 | Jan 13, 2010 | none ahead |
| Bristol-Myers Squibbits history only | 10 open or running | phase 1since Aug 26, 2014 | Aug 26, 2014 | none ahead |
| Dexcel Pharma Technologiesits history only | 10 open or running | phase 2since Dec 27, 2009 | Dec 27, 2009 | none ahead |
| Idorsia Pharmaceuticalsits history only | 10 open or running | phase 1since Feb 15, 2022 | Feb 15, 2022 | none ahead |
| Institut de Recherches Internationales Servier (I.R.I.S.)its history only | 10 open or running | phase 1since Nov 14, 2025 | Nov 14, 2025 | none ahead |
| Teikoku Seiyakuits history only | 10 open or running | phase 1since Jan 19, 2025 | Jan 19, 2025 | none ahead |
Also a collaborator on its studies: SocraMetrics and HWI pharma services.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 1, 2007First study: phase 1 study in AnemiaNew to GlaxoSmithKlineGlaxoSmithKline · NCT00443170 · 90 enrolled · Australia
- Feb 1, 2008Phase 1 study in Diabetes Mellitus, Type 2GlaxoSmithKline · NCT00615212 · 23 enrolled · United States
- Jul 23, 2009Phase 1 study in Drug InteractionsGlaxoSmithKline · NCT00964106 · 87 enrolled · Korea, Republic of
- Dec 27, 2009Dexcel Pharma Technologies’ first study: phase 2 study in PeriodontitisNew to Dexcel Pharma TechnologiesDexcel Pharma Technologies · NCT01040286 · Israel
- Jan 13, 2010Reckitt’s first studies: 2 phase 3 studies in PharyngitisNew to ReckittReckitt · NCT01049334, NCT01048866
- Oct 22, 2013Phase 3 study in PharyngitisReckitt · NCT01986361 · 122 enrolled · United States
- Aug 26, 2014Bristol-Myers Squibb’s first study: phase 1 study in Drug-drug Interaction StudyNew to Bristol-Myers SquibbBristol-Myers Squibb · NCT02227173 · 20 enrolled · United States
- Jun 5, 2020Phase 1 study in HIV InfectionsGlaxoSmithKline · NCT04425902 · 20 enrolled · United States
- Feb 15, 2022Idorsia Pharmaceuticals’ first study: phase 1 study in HealthyNew to Idorsia PharmaceuticalsIdorsia Pharmaceuticals · NCT05254548 · 22 enrolled · Germany
- Jan 19, 2025Teikoku Seiyaku’s first study: phase 1 study in HealthyNew to Teikoku SeiyakuTeikoku Seiyaku · NCT06823284 · 26 enrolled · Germany
- Nov 14, 2025Institut de Recherches Internationales Servier (I.R.I.S.)’s first study: phase 1 study in Healthy Adult ParticipantsNew to Institut de Recherches Internationales Servier (I.R.I.S.)Institut de Recherches Internationales Servier (I.R.I.S.) · NCT07235748 · 28 enrolled · United Kingdom
TargetBeta
“Cyclooxygenase inhibitor; Cyclooxygenase inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Acetaminophenrule | Johnson & Johnson | phase 4 | 136 |
| Ibuprofenrule | Pfizer | phase 4 | 113 |
| Aspirinrule | Bayer | phase 4 | 84 |
| dexketoprofenrule | Menarini Group | phase 4 | 8 |
| Sulfasalazinerule | Bristol-Myers Squibb | phase 4 | 7 |
| dexibuprofenrule | aponia-laboratories-inc | phase 4 | 6 |
| Benzydaminerule | Angelini Pharma | phase 4 | 4 |
| Dipyronerule | Hypera Pharma | phase 4 | 4 |
| Piroxicamrule | Taisho Pharmaceutical | phase 4 | 4 |
Studies
All 12 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07235748Healthy Adult Participants · United Kingdom | 1 | Completed | Institut de Recherches Internationales Servier (I.R.I.S.) | Dec 23, 2025 | 28 |
| NCT06823284Healthy · Germany | 1 | Completed | Teikoku Seiyaku | Feb 12, 2025 | 26 |
| NCT05254548Healthy · Germany | 1 | Completed | Idorsia Pharmaceuticals | Apr 13, 2022 | 22 |
| NCT04425902HIV Infections · United States | 1 | Completed | GlaxoSmithKline | Mar 10, 2021 | 20 |
| NCT02227173Drug-drug Interaction Study · United States | 1 | Completed | Bristol-Myers Squibb | Nov 2014 | 20 |
| NCT01986361Pharyngitis · United States | 3 | Completed | Reckitt | Apr 2014 | 122 |
| NCT01049334Pharyngitis · United States | 3 | Completed | Reckitt | Mar 2011 | 204 |
| NCT01048866Pharyngitis · United States | 3 | Completed | Reckitt | Mar 2011 | 198 |
| NCT01040286Periodontitis · Israel | 2 | Completed | Dexcel Pharma Technologies | ||
| NCT00964106Drug Interactions · Korea, Republic of | 1 | Completed | GlaxoSmithKline | Aug 29, 2011 | 87 |
| NCT00615212Diabetes Mellitus, Type 2 · United States | 1 | Completed | GlaxoSmithKline | Feb 15, 2008 | 23 |
| NCT00443170Anemia · Australia | 1 | Completed | GlaxoSmithKline | 90 |
How it is read
Names in the registry
- “Flurbiprofen”, 7 entries
- “flurbiprofen”, 2 entries
- “Flurbiprofen tablet”, 1 entry
- “Flurbiprofen 100 mg”, 1 entry
- “omeprazole, caffeine, flurbiprofen, rosiglitazone”, 1 entry
Conditions, from the studies’ own filings
- Pharyngitis, 3 studies
- HIV Infections, 1 study
- Diabetes Mellitus, Type 2, 1 study
- Anemia, 1 study
- Periodontitis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.